| Literature DB >> 21496434 |
Xinzhuo Wang1, Yukun Qin, Jundong Gu, Fengwei Wang, Peijie Jia, Hui Wang, Qiang Yao, Siwei Zhu.
Abstract
BACKGROUND ANDEntities:
Mesh:
Substances:
Year: 2011 PMID: 21496434 PMCID: PMC5999709 DOI: 10.3779/j.issn.1009-3419.2011.04.08
Source DB: PubMed Journal: Zhongguo Fei Ai Za Zhi ISSN: 1009-3419
纳入研究16篇文献的质量评价(STROBE声明)
STROBE statement-checklist criteria included in 16 reports of passive smoking and lung cancer risk
| Items | Recommendation | Number of stydy [ |
| Title and abstract | 1.1 Indicate the study’s design with a commonly used term in the title or the abstract | 6 (27.3%) |
| 1.2 Provide in the abstract an informative and balanced summary of what was done and what was found | 16 (72.7%) | |
| Introduction | ||
| Background/rationale | 2 Explain the scientific background and rationale for the investigation being reported | 17 (77.3%) |
| Objectives | 3 State specific objectives, including any prespecified hypotheses | 18 (81.8%) |
| Methods | ||
| Study desin | 4 Present key elemens of study design early in the paper | 15 (68.2%) |
| Setting | 5 Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection | 20 (90.9%) |
| Participants | 6.1 Give the eligibility criteria, and the sources and methods of ascertainment, and control selection. Give the rationale for the choice of cases and controls | 11 (50.0%) |
| 6.2 For matched studies, give matching criteria and the number of controls per case | 10 (45.5%) | |
| Variables | 7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable | 10 (45.5%) |
| Datasources/measurement | 8 For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | 12 (54.5%) |
| Bias | 9 Describe any efforts to address potential sources of bias | 3 (13.6%) |
| Study size | 10 Explain how the study size was arrived at | 0 (0) |
| Quantitative variables | 11 Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why | 11 (50.0%) |
| Statistical methods | 12.1 Describe all statistical methods, including those used to control for confounding | 16 (72.7%) |
| 12.2 Describe any methods used to examine subgroups and interactions | 14 (63.6%) | |
| 12.3 Explain how missing data were addressed | 9 (40.9%) | |
| 12.4 If applicable, explain how matching of cases and controls was addressed 12.5 Describe any sensitivity analyses | 11 (50.0%) | |
| Results | ||
| Participants | 13.1 Report numbers of individuals at each stage of study (eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed) | 16 (72.7%) |
| 13.2 Give reasons for non-participation at each stage | 8 (36.4%) | |
| 13.3 Consider use of a flow diagram | 2 (9.1%) | |
| Descriptive data | 14.1 Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders | 13 (59.1) |
| 14.2 Indicate number of participants with missing data for each variable of interest | 9 (40.9%) | |
| Outcome data | 15 Report numbers in each exposure category, or summary measures of exposure | 17 (77.3%) |
| 16.1 Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg 95% confidence interval). Make clear which confounders were adjusted for and why they were included | 12 (54.5%) | |
| 16.2 Report category boundaries when continuous variables were categorized | 14 (63.6%) | |
| 16.3 If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period | 6 (27.3%) | |
| Other analyses | 17 Report other analyses done (eg analyses of subgroups and interactions, and sensitivity analyses) | 7 (31.8%) |
| Discusion | ||
| Key results | 18 Summarise key results with reference to study objectives | 22 (100%) |
| Limitations | 19 Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias | 12 (54.5%) |
| Interpretation | 20 Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence | 11 (50.0%) |
| Generalisability | 21 Discuss the generalisability (external validity) of the study results | 7 (12.7%) |
| Other information | ||
| Funding | 22 Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based | 9 (40.9%) |
纳入研究的基本特征
General characteristics of included trials
| Reference | No. of patients | Gender | QS% | OR | 95%CI | Time period | Year of publication | Location |
| Kabat[ | 53 | Female | 65 | 0.7 | 0.3-1.5 | 1971-1980 | 1984 | USA |
| Garfinkel[ | 76 | Female | 62 | 0.9 | 0.7-1.2 | 1971-1981 | 1985 | USA |
| Wu[ | 29 | Female | 67 | 1.3 | 0.3-3.3 | 1981-1982 | 1985 | USA |
| Lee[ | 15 | Female | 72 | 0.6 | 0.2-2.3 | 1979-1982 | 1986 | England |
| Shimizu[ | 90 | Female | 66 | 1.2 | 0.6-2.6 | 1982-1985 | 1988 | Japan |
| Kalandidi[ | 89 | Female | 70 | 1.4 | 0.8-2.5 | 1987-1989 | 1990 | Greece |
| Wu-Williams[ | 415 | Female | 71 | 1.2 | 0.9-1.6 | 1985-1987 | 1990 | China |
| Kabat[ | 58 | Female | 65 | 1.2 | 0.6-2.1 | 1983-1990 | 1995 | USA |
| Reynolds[ | 528 | Female | 68 | 1.6 | 1.2-2.0 | 1986-1990 | 1996 | USA |
| Sun[ | 230 | Female | 71 | 1.4 | 0.9-2.0 | Not report | 1994 | China |
| Wang[ | 135 | Female | 62 | 0.9 | 0.5-1.8 | 1992-1994 | 1994 | China |
| Zaridze[ | 189 | Female | 75 | 0.9 | 0.6-1.4 | Not report | 1998 | Russia |
| Zong[ | 504 | Female | 72 | 1.7 | 1.3-2.3 | 1992-1994 | 1999 | China |
| Lee[ | 268 | Female | 73 | 1.5 | 0.5-2.4 | 1992-1998 | 2000 | Taiwan |
| Johnson[ | 71 | Female | 71 | 1.3 | 0.4-4.0 | 1994-1997 | 2001 | Canada |
| Kabat[ | 25 | Male | 65 | 3.3 | 1.0-10.6 | 1971-1980 | 1984 | USA |
| Lee[ | 10 | Male | 72 | 1.6 | 0.4-6.6 | 1979-1982 | 1986 | England |
| Kabat[ | 41 | Male | 76 | 1.0 | 0.5-2.1 | 1983-1990 | 1995 | USA |
| Schwartz[ | 257 | Male/Female | 77 | 1.5 | 1.0-2.2 | 1984-1987 | 1996 | USA |
| Boffetta[ | 650 | Male/Female | 71 | 1.2 | 0.9-1.5 | 1988-1994 | 1998 | Europe |
| Boffetta[ | 70 | Male/Female | 63 | 1.5 | 0.8-3.0 | 1994-1996 | 1999 | Europe |
| Rapiti[ | 58 | Male/Female | 64 | 1.1 | 0.3-4.1 | 1991-1992 | 1999 | India |
| Kreuzer[ | 123 | Male/Female | 77 | 1.1 | 0.7-1.7 | 1990-1996 | 2000 | Germany |
| Wang[ | 233 | Male/Female | 70 | 1.6 | 0.7-3.3 | 1994-1998 | 2000 | China |
1工作环境烟草暴露与非吸烟人群肺癌发生危险的森林图
Forest plot of workplace environmental tobacco smoke exposure and lung cancer risk
2工作环境烟草暴露与肺癌发生危险的漏斗图
The funne plot for workplace environmetal tobacco smoke and lung cancer risk
3各篇文献对meta分析结果的影响
The influence of each trial for the outcome of the systematic review